Oncolytics Biotech Inc. – Product Pipeline Review – Q1 2011

Document Sample
Oncolytics Biotech Inc. – Product Pipeline Review – Q1 2011 Powered By Docstoc
					    Oncolytics Biotech Inc. – Product Pipeline Review –
                         Q1 2011
                                                                                          Reference Code: GMDHC1200CDB

                                                                                                Publication Date: MAY 2011




Oncolytics Biotech Inc. – Product Pipeline Review – Q1 2011                                 GMDHC1200CDB / Published MAY 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Oncolytics Biotech Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Oncolytics Biotech Inc. Snapshot                                                                                      5
    Oncolytics Biotech Inc. Overview                                                                                  5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Oncolytics Biotech Inc. – Research and Development Overview                                                           6
    Key Therapeutic Areas                                                                                             6
Oncolytics Biotech Inc. – Pipeline Review                                                                             9
    Pipeline Products by Stage of Development                                                                         9
    Pipeline Products – Monotherapy                                                                                  10
    Pipeline Products – Combination Treatment Modalities                                                             11
Oncolytics Biotech Inc. – Pipeline Products Glance                                                                   12
    Oncolytics Biotech Inc. Clinical Stage Pipeline Products                                                         12
         Phase II Products/Combination Treatment Modalities                                                          12
         Phase I Products/Combination Treatment Modalities                                                           13
    Oncolytics Biotech Inc.–Early Stage Pipeline Products                                                            14
         Pre-Clinical Products/Combination Treatment Modalities                                                      14
Oncolytics Biotech Inc. – Drug Profiles                                                                              15
    Reolysin                                                                                                         15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    Reolysin + Gemzar                                                                                                17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    REOLYSIN + Paclitaxel                                                                                            19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    Reolysin + Paclitaxel + Carboplatin                                                                              21
         Product Description                                                                                         21
         Mechanism of Action                                                                                         21
         R&D Progress                                                                                                22
    Reolsyin + Docetaxel                                                                                             24
         Product Description                                                                                         24
         Mechanism of Action                                                                                         24
         R&D Progress                                                                                                24
    Reolysin                                                                                                         25
         Product Description                                                                                         25
         Mechanism of Action                                                                                         25
         R&D Progress                                                                                                25
    Reolysin + Cyclophosphamide                                                                                      27
         Product Description                                                                                         27




Oncolytics Biotech Inc. – Product Pipeline Review – Q1 2011                               GMDHC1200CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Oncolytics Biotech Inc. – Product Pipeline Review



         Mechanism of Action                                                                                         27
         R&D Progress                                                                                                27
    Reolysin + FOLFIRI                                                                                               28
         Product Description                                                                                         28
         Mechanism of Action                                                                                         28
         R&D Progress                                                                                                29
    Reolysin + Cisplatin                                                                                             30
         Product Description                                                                                         30
         Mechanism of Action                                                                                         30
         R&D Progress                                                                                                30
Oncolytics Biotech Inc. – Pipeline Analysis                                                                          31
    Oncolytics Biotech Inc. – Pipeline Products by Therapeutic Class                                                 31
    Oncolytics Biotech Inc. - Pipeline Products By Target                                                            33
    Oncolytics Biotech Inc. – Pipeline Products by Route of Administration                                           34
    Oncolytics Biotech Inc. – Pipeline Products by Molecule Type                                                     35
Oncolytics Biotech Inc. – Recent Pipeline Updates                                                                    36
Oncolytics Biotech Inc. – Company Statement                                                                          38
Oncolytics Biotech Inc. – Locations And Subsidiaries                                                                 41
    Head Office                                                                                                      41
    Other Locations & Subsidiaries                                                                                   41
Financial Deals Landscape                                                                                            42
    Oncolytics Biotech Inc., Deals Volume Summary, 2004 to YTD 2011                                                  42
    Oncolytics Biotech Inc., Deals Summary By Region, 2004 to YTD 2011                                               43
    Oncolytics Biotech Inc., Deals Summary, 2004 to YTD 2011                                                         44
    Oncolytics Biotech Inc. Detailed Deal Summary                                                                    45
         Acquisition                                                                                                 45
         Oncolytics Acquires 10% Stake In British Canadian Biosciences                                               45
         Equity Offering                                                                                             46
         Oncolytics Biotech Announces Exercise Of Underwriter's Allotment Option                                     46
         Oncolytics Biotech Completes Public Offering Of $6 Million                                                  48
         Oncolytics Biotech Completes Public Offering Of $3 Million                                                  50
         Oncolytics Biotech Completes Public Offering Of $12 Million                                                 52
         Oncolytics Biotech Completes Private Placement Of $16 Million                                               54
         Oncolytics Biotech Completes Private Placement Of $8.28 Million                                             56
         Oncolytics Biotech Completes Private Placement Of $5 Million                                                58
Appendix                                                                                                             60
    Methodology                                                                                                      60
         Coverage                                                                                                    60
         Secondary Research                                                                                          60
         Primary Research                                                                                            60
         Expert Panel Validation                                                                                     61
    Contact Us                                                                                                       61
    Disclaimer                                                                                                       61




Oncolytics Biotech Inc. – Product Pipeline Review – Q1 2011                               GMDHC1200CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(3)
Oncolytics Biotech Inc. – Product Pipeline Review




Lis t o f Ta b le s
Oncolytics Biotech Inc. – Pipeline by Therapy Are
				
DOCUMENT INFO
Description: Oncolytics Biotech Inc. – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Oncolytics Biotech Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Oncolytics Biotech Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Oncolytics Biotech Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Oncolytics Biotech Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Oncolytics Biotech Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Oncolytics Biotech Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Oncolytics Biotech Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Oncolytics Biotech Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensi
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries